Earnings Call Excerpt
Provectus Pharmaceuticals Inc. (PVCT)
Wall Street Analyst Forum
September 10, 2008 11:50 am ET
Executives
Craig Dees - CEO
Peter Culpepper - CFO
Presentation
Moderator
Good morning, ladies and gentlemen. In our ongoing attempt to adhere to the published schedule as much for the analysts that are here, as for the investors who access the webcast from wherever they maybe, Boston, London, New York, Chicago or the building across the street, I would like to introduce the next company in this program.
As I have alluded to earlier in the day, the webcast are live. They are also retrievable for 30 days. It is both the audio portion of the presentation as well as the PowerPoint part of the presentation.
We also use a firm called seekingalpha.com. They are actually from Israel. They tap into the webcast. They do a transcript of the presentation and the Q&A session, and those are web-searchable on the major financial portals like Google Finance.
So, if some investor from anywhere in the world takes a couple of hours to do it, but say six hours from now looks up for this company on Google Finance under Beijing, China, they will have a transcript of this presentation, including what I am saying right now, word-for-word. I can go back and see that word-for-word in six hours from anywhere in the world.
Some investors find that actually more helpful than the webcast. 40 minutes is a long time to hang on for a webcast whereas you can all tend to get everything you need in 5.5 minutes by going through the key points of the transcript and having that that way. So, it is one more distribution channel for us, using the major financial portals of Google Finance, Yahoo! Finance, AOL Finance, MSN Money and the rest; arguably in some cases more effective than the webcast, because it is so easily accessible.
In any case, I would like to introduce the next company in this morning's program. Provectus Pharmaceuticals is a development stage company that specializes in development of oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs, PV-10, as a therapy for metastatic melanoma and PH-10 as topical treatment for psoriasis and atopic dermatitis.
Information about these and the company's other clinical trials can be found at the NIH Registry, clincaltrials.gov.
- To read the full transcript on Seeking Alpha, click here »
